The Medicines Company looks strong ahead of the FDA decisions later this month $MDCO

By |August 24th, 2017|Monthly Investment Ideas|

The Medicines Company ($MDCO) recently reported its second quarter results as the company also provided details about its corporate developments. The Medicines Company’s global net revenue stood at $18.7 million, in comparison to $54.7 million it had reported for the second quarter of the previous year. The company’s net loss [...]

Premarket Biotech Digest – $ACIU announces new discovery, $PMD launches new test, $NSPR receives NYSE notice

By |August 23rd, 2017|Digest|

AC Immune SA ($ACIU) stock perked up as the company announced the discovery of two new antibodies using its proprietary SupraAntigen platform. These antibodies will be used against two targets in the pathogenesis of neurodegenerative diseases. The first is Alpha-synuclein, an established target for [...]

Intersect posts strong Q2 numbers, looks forward to FDA ruling for Sinuvatm ($XENT)

By |August 22nd, 2017|Monthly Investment Ideas|

Intersect ENT Inc. ($XENT) specializes in Ear, Nose and Throat segment where it develops and markets novel drugs devices. It focuses on providing innovating implants for treating various conditions related to ear, nose and throat. The company recently reported its second quarter results where its revenue stood at $24 million, [...]

Premarket Biotech Digest – $WINT announces financial restructuring, $JNJ gets positive court verdict, $BIOC inks new deal

By |August 21st, 2017|Digest|

Ritter Pharmaceuticals ($RTTR) provided details about the Phase 3 program for lactose intolerance (LI) candidate RP-G28. The program incorporates guidance from the FDA during their End-of-Phase 2 meeting. The two studies to be conducted under this phase will both have the change in LI [...]

Premarket Biotech Digest – $GMED receives clearance, $BIOC inks new collaboration, $PFE receives approval

By |August 18th, 2017|Digest|

Opko Health Inc. ($OPK) announced inking a commitment letter with Veterans Accountable Care Group, LLC. The collaboration is related to a Veterans Health Administration (VHA) contract. If the bid turns out to be successful then Opko will acquire a 15% stake in VACO. It [...]

Clovis stock looks promising with strong Rubraca sales numbers $CLVS

By |August 17th, 2017|Monthly Investment Ideas|

Clovis Oncology Inc. ($CLVS) recently announced its second quarter financial results. The company also provided updates about its lead product Rubraca, which was launched in December, 2016. Clovis reported net product revenue for the drug at $14.6 million for the quarter, up from $7 million it had announced for the [...]

Premarket Biotech Digest – $COCP reports data, $SUPN gets favorable ruling, $FOLD receives approval

By |August 16th, 2017|Digest|

VBI Vaccines ($VBIV) announced that the FDA has approved its Investigational New Drug Application (IND) for immunotherapy candidate VBI-1901. The drug candidate is seeking approval as the potential treatment of Glioblastoma Multiforme (GBM), a common and aggressive type of malignant brain tumor. The IND [...]

Verastem stock to retain momentum with strong trial data $VSTM

By |August 15th, 2017|Monthly Investment Ideas|

Verastem Inc. ($VSTM) stock showed impressive performance this year by registering over 177 growth. The company recently reported its second quarter results with its net loss for the period at $13.4 million, up from a net loss of $8.6 million for the corresponding quarter of the previous year. However, the [...]

Premarket Biotech Digest – $SNGX receives funding, $ISRG board approves split, $SHPG receives Canadian approval

By |August 14th, 2017|Digest|

Achieve Life Sciences Inc. (NASDAQ:ACHV) stock perked up as the company announced received the FDA approval for its IND seeking approval to start U.S. clinical trials assessing smoking cessation drug cytosine. The company has already completed two large-scale Phase 3 studies, TASC and CASCAID, [...]

Premarket Biotech Digest – $SGMO announces strong quarterly numbers, $APEN receives FDA alert, $CELG modifies collaboration

By |August 11th, 2017|Digest|

Sangamo Therapeutics ($SGMO) shot up as the company announced better than expected quarterly numbers. For the second quarter ended June 30, 2017, the company reported a consolidated net loss of $12.5 million, or $0.17 per share, compared to a net loss of $26.6 million, [...]

The Medicines Company stock set to benefit from strong quarterly numbers $MDCO

By |August 10th, 2017|Monthly Investment Ideas|

The Medicines Company ($MDCO) stock showed positive reaction to its second quarter earnings announcement. The company reported its global revenue for the quarter at $18.7 million. The revenue figure included $10.7 million as aggregate revenue from Angiomax. Minocin and Orbactive recorded aggregate sales of $8.0 million in the second quarter [...]

Premarket Biotech Digest – $CLRB reports positive results, $TNDM receives new patent, $DERM inks new deal

By |August 9th, 2017|Digest|

Anthera Pharmaceuticals ($ANTH) stock shot up as the company announced that the FDA has designated its blisibimod an Orphan Drug for the treatment of immunoglobulin A nephropathy. The condition is also known as Berger's disease and is a disorder in which IgA builds up [...]

Aclaris files Marketing Authorization Application in EU, creating a new stock catalyst $ACRS

By |August 8th, 2017|Monthly Investment Ideas|

Aclaris Therapeutics ($ACRS) stock presents a strong investment opportunity as the company is awaiting the FDA approval for its Seborrheic Keratosis treatment. Its lead drug candidate A-101 is a strong contender to become the first FDA approved treatment for the condition. The company has already received a Notice of Allowance [...]

Premarket Biotech Digest – $TEVA gets FDA approval, $IMMY under investigation, $FOLD reports quarterly numbers

By |August 7th, 2017|Digest|

Athersys ($ATHX) announced that the European Medicine Agency has decided that the design of its Phase 3 clinical trial, MASTERS-2, assessing its MultiStem cell therapy product in patients with ischemic stroke should be sufficient to support approval. The decision is in line with with [...]

Premarket Biotech Digest – $LLY announces +ve results, $VTVT receives new patent, $ACRS files marketing application

By |August 4th, 2017|Digest|

Eli Lilly ($LLY) announced results from a second Phase 3 clinical trial assessing its lasmiditan for the acute treatment of migraine, which met its primary endpoint. The results were consistent with the first Phase 3, SAMURAI, reported about a year ago. At two hours [...]

Ultragenyx Pharmaceuticals stock to benefit from better than expected quarterly numbers $RARE

By |August 3rd, 2017|Monthly Investment Ideas|

Ultragenyx Pharmaceuticals Inc. ($RARE) announced its better than expected quarterly results, providing a further fillip to its stock price. The stock is currently nearly 30 percent below its 52 weeks high of $91.35 and is in recovery mode. The positive quarterly earnings and its robust pipeline are expected to fuel [...]

Premarket Biotech Digest – $VRTX gets FDA approval, $EYEG starts enrollment, $SGEN announces new deal

By |August 2nd, 2017|Digest|

AstraZeneca ($AZN) reported receiving Breakthrough Therapy designation for its acalabrutinib for treating patients with mantle cell lymphoma who have received at least one prior line of therapy. The therapy is currently in a Phase 2 clinical trial. it is an orally available second generation [...]

Neurocrine Biosciences a strong buy ahead of earnings announcement $NBIX

By |August 1st, 2017|Monthly Investment Ideas|

Neurocrine Biosciences Inc. ($NBIX) is set to announce its second quarter earnings on August 3rd. The company is expected to provide update about its recently approved Ingrezza capsules. This is the first FDA approved therapy for treating Tardive Dyskinsia (TD). The company had reported a net loss of $0.90 per [...]

Premarket Biotech Digest – $GILD receives EU approval, $IVC changes production site, $CYTR inks new deal

By |July 31st, 2017|Digest|

Dynavax Techologies ($DVAX) stock perked up as the company announced that an FDA advisory panel voted 12-1 in favor of the available data for is hepatitis B vaccine for adults. The advisory panel is of the view that the data supports the safety profile [...]

Premarket Biotech Digest – $CERS inks new deal, $IDXG reports CIGNA coverage, $AZN announces negative results

By |July 28th, 2017|Digest|

Cerus Corporation ($CERS) stock perked up as the company announced inking deal with the Central California Blood Center. The new deal pertains to the company’s INTERCEPT plasma. The Center will use the plasma for manufacturing pathogen-reduced cryoprecipitate, to control bleeding in patients with acquired [...]

s2Member®